Antony Blanc
Corporate Officer/Principal bei CUREVAC N.V.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ulrike Gnad-Vogt | M | - | 13 Jahre | |
| Michael Brosnan | M | 69 | 1 Jahre | |
| Sarah Fakih | M | - | - | |
| Craig Tooman | M | 58 | 5 Jahre | |
| Klaus Schollmeier | M | 67 | 2 Jahre | |
| Baron Jean Stéphenne | M | 73 | 9 Jahre | |
| Pierre Kemula | M | 50 | 8 Jahre | |
| Alexander Zehnder | M | 54 | 1 Jahre | |
| Tobias Ohler | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 27 Jahre |
| Mathias Hothum | M | 58 | 9 Jahre | |
| Debra Stephanie Barker | M | 61 | 2 Jahre | |
| Viola Bronsema | M | 61 | 4 Jahre | |
| Malte Greune | M | 59 | 3 Jahre | |
| Patrick Baumhof | M | - | - | |
| Bettina Jödicke-Braas | F | - | - | |
| Myriam Mendila | M | 58 | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mark Moran | M | 64 |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | - |
| John Ramsay | M | 66 | 16 Jahre | |
| Michael Pragnell | M | 77 | 7 Jahre | |
| Robert Berendes | M | 59 | 12 Jahre | |
| Gavin Hill | M | 56 | 2 Jahre | |
| Felix Weber | M | 73 | 13 Jahre | |
| Ralph Heck | M | 67 |
Mckinsey & Co., Inc. (Germany)
| 28 Jahre |
| John Atkin | M | 70 | 14 Jahre | |
| Michael T. Mack | M | 64 | 7 Jahre | |
| Alejandro A. Aruffo | M | 63 | 5 Jahre | |
| Rolf Urs Watter | M | 66 | 12 Jahre | |
| Pierre Landolt | M | 77 | 12 Jahre | |
| Peter M. Thompson | M | 77 | 13 Jahre | |
| Peggy Bertha Bruzelius | F | 74 | 13 Jahre | |
| Jacques Vincent | M | 78 | - | |
| Florian von der Muelbe | M | 52 | 21 Jahre | |
| Sabine Bendiek | F | 58 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Arno Antlitz | M | 54 |
Mckinsey & Co., Inc. (Germany)
| - |
| Andreas Ulf Krinninger | M | 56 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| Mariola Fotin-Mleczek | M | 50 | 16 Jahre | |
| Michael Escher | M | - | 5 Jahre | |
| Jeffrey R. Beard | M | - | 20 Jahre | |
| Ralf Clemens | M | 71 | 8 Jahre | |
| Günther Thallinger | M | 52 |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Simon Lees | M | - | 3 Jahre | |
| Michael Erich Matthias Hammes | M | 69 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| Timothy M. Wright | M | 69 | 3 Jahre | |
| Marcus Johannes Chromik | M | 52 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Timm Richter | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| Simon Warner | M | - | 6 Jahre | |
| Markus Scheuermann | M | 51 |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
| Christoph Mäder | M | 64 | 18 Jahre | |
| Andreas Wolf | M | - |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Mrinay Nair | M | - |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Igor Splawski | M | 56 | 3 Jahre | |
| Bernd Winterhalter | M | 65 | 2 Jahre | |
| Michael Rudolf | M | 50 |
Mckinsey & Co., Inc. (Germany)
| 10 Jahre |
| Jochen Linck | M | 57 |
Mckinsey & Co., Inc. (Germany)
| 11 Jahre |
| Achim Dünnwald | M | 55 |
Mckinsey & Co., Inc. (Germany)
| 12 Jahre |
| Sopna Sury | M | 50 |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
| Erik Stefan Leyers | M | 54 |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Klaus Edvardsen | M | 62 | 1 Jahre | |
| Philipp Carlsson-Szlezak | M | - |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Damian Heller | M | 58 | 7 Jahre | |
| Stefan Blarer | M | - | 6 Jahre | |
| Yassin Hankir | M | - |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Bettina Orlopp | M | 53 |
Mckinsey & Co., Inc. (Germany)
| - |
| Arnoud A. Middel | M | 53 | 3 Jahre | |
| John Kristin Sirchio | M | 58 | 5 Jahre | |
| Florian Kawohl | M | - |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Richard Steiblin | M | 74 | 3 Jahre | |
| Dorothea Wenzel | M | 55 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| André Krause | M | 54 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| Stephen L. Bandak | M | 74 |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | 4 Jahre |
| Christian Diekmann | M | 58 |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Gert Purkert | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Dirk Markus | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Stefan Borgas | M | 59 | 8 Jahre | |
| Frank Appel | M | 62 |
Mckinsey & Co., Inc. (Germany)
| 1 Jahre |
| Rupert Gasser | M | - | 7 Jahre | |
| Peter Doyle | M | - | 9 Jahre | |
| Domenico Scala | M | 59 | 4 Jahre | |
| David Lawrence | M | 75 | 8 Jahre | |
| Heinz Imhof | M | - | 5 Jahre | |
| Desmond J. Fitzgerald | M | - |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | - |
| Zachary McNealy | M | 50 |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | 3 Jahre |
| Uwe Meya | M | - |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | - |
| Christoph Vilanek | M | 56 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Leonhard Birnbaum | M | 57 |
Mckinsey & Co., Inc. (Germany)
| 12 Jahre |
| Stephan Kirschbaum | M | 57 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| Dirk W. Kirsten | M | 56 | 4 Jahre | |
| Antoinette P. Aris | F | 65 |
Mckinsey & Co., Inc. (Germany)
| 18 Jahre |
| Martin Taylor | M | 71 | 13 Jahre | |
| Mark Peacock | M | 63 | 10 Jahre | |
| Franz-Werner Haas | M | 54 | 11 Jahre | |
| Benedikt Timmerman | M | 65 | 3 Jahre | |
| Jürg Witmer | M | 75 | - | |
| Christopher Hoffmann | M | 50 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| Davor Pisk | M | 66 | 8 Jahre | |
| Stephan Leithner | M | 58 |
Mckinsey & Co., Inc. (Germany)
| 7 Jahre |
| Hans Tanner | M | 72 | 8 Jahre | |
| Thomas Vollmoeller | M | 64 |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
| Kristian Schleede | M | 66 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| Michaela Schäfer | M | - |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Deutschland | 60 | 60,00% |
| Schweiz | 40 | 40,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Antony Blanc
- Persönliches Netzwerk
